The bone-marrow niche in MDS and MGUS: implications for AML and MM

Nature Reviews. Clinical Oncology
Irene M GhobrialDavid P Steensma

Abstract

Several haematological malignancies, including multiple myeloma (MM) and acute myeloid leukaemia (AML), have well-defined precursor states that precede the development of overt cancer. MM is almost always preceded by monoclonal gammopathy of undetermined significance (MGUS), and at least a quarter of all patients with myelodysplastic syndromes (MDS) have disease that evolves into AML. In turn, MDS are frequently anteceded by clonal haematopoiesis of indeterminate potential (CHIP). The acquisition of additional genetic and epigenetic alterations over time clearly influences the increasingly unstable and aggressive behaviour of neoplastic haematopoietic clones; however, perturbations in the bone-marrow microenvironment are increasingly recognized to have key roles in initiating and supporting oncogenesis. In this Review, we focus on the concept that the haematopoietic neoplasia-microenvironment relationship is an intimate rapport between two partners, provide an overview of the evidence supporting a role for the bone-marrow niche in promoting neoplasia, and discuss the potential for niche-specific therapeutic targets.

References

Nov 24, 1999·The New England Journal of Medicine·S SinghalB Barlogie
Dec 12, 2001·Seminars in Oncology·S V Rajkumar, R A Kyle
Jul 2, 2002·Blood·Yang YangRalph D Sanderson
Nov 5, 2002·Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research·G David Roodman
Jan 15, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·E VerburghG Verhoef
Apr 12, 2003·Leukemia & Lymphoma·Alvaro AguayoMaher Albitar
Dec 21, 2004·Leukemia Research·Eugenia Flores-FigueroaHector Mayani
Mar 11, 2005·The New England Journal of Medicine·Guenter Weiss, Lawrence T Goodnough
Jun 7, 2005·Expert Opinion on Therapeutic Targets·Klaus PodarKenneth C Anderson
Jun 22, 2006·Future Oncology·Alissa Huston, G David Roodman
Jul 11, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Wolfgang A Weber
Oct 26, 2006·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·G David Roodman
May 4, 2007·The Journal of Clinical Investigation·Jeremy B Swann, Mark J Smyth
Nov 23, 2007·The New England Journal of Medicine·Meletios DimopoulosUNKNOWN Multiple Myeloma (010) Study Investigators
Dec 7, 2007·Hormones : International Journal of Endocrinology and Metabolism·Maria P Yavropoulou, John G Yovos
Dec 12, 2007·Best Practice & Research. Clinical Haematology·Klaus PodarKenneth C Anderson
Mar 12, 2008·Blood·Robert A Kyle, S Vincent Rajkumar
Apr 10, 2008·Blood·Thalia Papayannopoulou, David T Scadden
Nov 29, 2008·Leukemia·G D Roodman
Feb 7, 2009·Nature Reviews. Immunology·Dmitry I Gabrilovich, Srinivas Nagaraj
Feb 24, 2009·Blood·Brendan M WeissW Michael Kuehl

❮ Previous
Next ❯

Citations

Apr 28, 2018·Wiley Interdisciplinary Reviews. Nanomedicine and Nanobiotechnology·Alexander ZheleznyakSamuel Achilefu
May 18, 2019·American Society of Clinical Oncology Educational Book·Amy E DeZernBenjamin L Ebert
Jul 22, 2019·Journal of Clinical Medicine·Antonio Giovanni SolimandoHermann Einsele
Oct 16, 2019·American Journal of Hematology·Abdullah S Al SalehShaji K Kumar
Jan 28, 2020·Blood Advances·Haydar ÇelikChristopher S Hourigan
Jan 31, 2020·International Journal of Cancer. Journal International Du Cancer·Gregory S CalipBrian C-H Chiu
Mar 20, 2020·Expert Opinion on Therapeutic Targets·Lena BehrmannWalter Fiedler
May 10, 2018·Frontiers in Oncology·Noboru Asada
Jan 16, 2019·The Journal of Immunology : Official Journal of the American Association of Immunologists·Sophie StephensonReuben M Tooze
Feb 26, 2020·Blood Advances·Amy E DeZern, Lukasz P Gondek
Sep 15, 2020·FASEB BioAdvances·Natasha L FriendAndrew C W Zannettino
Jul 10, 2020·Blood·Kyohei NakamuraLudovic Martinet
Oct 4, 2018·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Jacob P LaubachIrene M Ghobrial
Apr 29, 2018·Cancer Research·Niels van NieuwenhuijzenVictor Peperzak
Aug 8, 2020·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Francesco MauraGareth J Morgan
Aug 19, 2020·Blood Reviews·Yan ChengSiegfried Janz
Jan 13, 2021·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Sophia KhaldoyanidiMarion Subklewe
Nov 11, 2019·Trends in Cancer·Matthew T WitkowskiIannis Aifantis
Jan 20, 2021·Nature Communications·Antonio Garcia-GomezEsteban Ballestar
Jan 14, 2021·Cancers·Almudena García-OrtizJoaquín Martínez-López
Feb 1, 2021·Lancet·Niels W C J van de DonkKwee L Yong
Mar 7, 2020·Best Practice & Research. Clinical Haematology·Kylee MaclachlanDickran Kazandjian
Mar 9, 2021·Tissue Engineering. Part B, Reviews·Cláudia S OliveiraJoão F Mano
Mar 16, 2021·Frontiers in Immunology·Samuel S McCachrenMadhav V Dhodapkar
Sep 3, 2020·British Journal of Pharmacology·Shuting SunFrank H Ebetino
May 22, 2021·Nature Immunology·Madelon M E de JongTom Cupedo
Jun 2, 2021·Cancer Immunology, Immunotherapy : CII·Morten N AndersenHolger J Møller

❮ Previous
Next ❯

Related Concepts

Related Feeds

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Cancer Epigenetics & Metabolism (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. This feed focuses on the relationship between cell metabolism, epigenetics and tumor differentiation.

Cancer Epigenetics & Methyl-CpG (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. Here is the latest research on cancer epigenetics and methyl-CpG binding proteins including ZBTB38.

Cancer Epigenetics and Senescence (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may be involved in regulating senescence in cancer cells. This feed captures the latest research on cancer epigenetics and senescence.

Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

Cancer Epigenetics

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.

Cell Signaling & Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. This feed covers the latest research on signaling and epigenetics in cell growth and cancer.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.